China Resources Pharmaceutical Group Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
China Resources Pharmaceutical Group is forecast to grow earnings and revenue by 7.5% and 7.8% per annum respectively. EPS is expected to grow by 7.2% per annum. Return on equity is forecast to be 6% in 3 years.
Wichtige Informationen
7.5%
Wachstumsrate der Gewinne
7.2%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 11.1% |
| Wachstumsrate der Einnahmen | 7.8% |
| Zukünftige Eigenkapitalrendite | 6.0% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 04 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up
Oct 07
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 315,657 | 5,094 | 9,012 | 14,313 | 8 |
| 12/31/2025 | 287,282 | 4,657 | 7,498 | 11,479 | 10 |
| 12/31/2024 | 263,073 | 4,249 | 7,282 | 16,640 | 9 |
| 6/30/2024 | 250,483 | 3,777 | 15,278 | 18,300 | N/A |
| 3/31/2024 | 247,593 | 3,816 | 13,914 | 16,925 | N/A |
| 12/31/2023 | 244,704 | 3,854 | 12,550 | 15,550 | N/A |
| 9/30/2023 | 232,564 | 3,573 | 10,223 | 12,883 | N/A |
| 6/30/2023 | 224,656 | 3,382 | 7,697 | 10,053 | N/A |
| 3/31/2023 | 224,587 | 3,518 | 7,847 | 10,355 | N/A |
| 12/31/2022 | 218,183 | 3,500 | 8,239 | 10,821 | N/A |
| 9/30/2022 | 221,487 | 3,724 | 7,431 | 10,371 | N/A |
| 6/30/2022 | 211,788 | 3,719 | 6,240 | 9,347 | N/A |
| 3/31/2022 | 196,226 | 3,288 | 6,935 | 9,628 | N/A |
| 12/31/2021 | 193,021 | 3,072 | 8,009 | 10,468 | N/A |
| 9/30/2021 | 191,495 | 2,869 | 5,958 | 8,155 | N/A |
| 6/30/2021 | 187,554 | 2,626 | 3,792 | 5,694 | N/A |
| 3/31/2021 | 179,512 | 2,720 | 4,521 | 6,344 | N/A |
| 12/31/2020 | 168,762 | 2,776 | 5,194 | 6,910 | N/A |
| 9/30/2020 | 171,873 | 2,683 | 6,986 | 8,696 | N/A |
| 6/30/2020 | 174,956 | 2,578 | 8,914 | 10,616 | N/A |
| 3/31/2020 | 181,054 | 2,793 | 7,272 | 9,038 | N/A |
| 12/31/2019 | 182,690 | 2,937 | 5,488 | 7,274 | N/A |
| 9/30/2019 | 183,417 | 3,670 | 5,658 | 7,406 | N/A |
| 6/30/2019 | 173,938 | 4,187 | 5,510 | 7,124 | N/A |
| 3/31/2019 | 165,679 | 3,737 | 5,370 | 6,990 | N/A |
| 12/31/2018 | 166,626 | 3,494 | 5,528 | 7,244 | N/A |
| 9/30/2018 | 163,734 | 3,466 | 4,984 | 6,419 | N/A |
| 6/30/2018 | 154,852 | 3,309 | 4,276 | 5,387 | N/A |
| 3/31/2018 | 142,296 | 2,959 | N/A | 4,493 | N/A |
| 12/31/2017 | 143,688 | 2,901 | N/A | 4,045 | N/A |
| 9/30/2017 | 143,252 | 2,759 | N/A | 1,486 | N/A |
| 6/30/2017 | 142,276 | 2,602 | N/A | -1,189 | N/A |
| 3/31/2017 | 142,003 | 2,577 | N/A | 1,219 | N/A |
| 12/31/2016 | 140,316 | 2,526 | N/A | 3,689 | N/A |
| 9/30/2016 | 132,253 | 2,161 | N/A | 4,391 | N/A |
| 6/30/2016 | 129,313 | 1,889 | N/A | 5,222 | N/A |
| 3/31/2016 | 123,770 | 2,103 | N/A | 5,027 | N/A |
| 12/31/2015 | 122,785 | 2,388 | N/A | 5,017 | N/A |
| 12/31/2014 | 108,575 | 2,116 | N/A | 3,349 | N/A |
| 12/31/2013 | 91,313 | 2,061 | N/A | 3,203 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 3320's forecast earnings growth (7.5% per year) is above the savings rate (2.3%).
Ertrag vs. Markt: 3320's earnings (7.5% per year) are forecast to grow slower than the Hong Kong market (11.5% per year).
Hohe Wachstumserträge: 3320's earnings are forecast to grow, but not significantly.
Einnahmen vs. Markt: 3320's revenue (7.8% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).
Hohe Wachstumseinnahmen: 3320's revenue (7.8% per year) is forecast to grow slower than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 3320's Return on Equity is forecast to be low in 3 years time (6%).